Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-12. (cancelled)

13. (previously presented) A method of treating a patient having a disease state involving intravascular coagulation selected from the group consisting of thrombotic stroke, deep vein thrombosis, pulmonary embolism, peripheral arterial thrombosis, emboli originating from the heart or peripheral arteries, acute myocardial infarction, disseminated intravascular coagulation, and acute pre or postcapillary occlusions,

wherein said method comprises administering to said patient a lyophilized formulation comprising a weight to weight ratio of about 1 part activated protein C to between about 5 to 7 parts bulking agent.

14. (previously presented) The method of Claim 13 wherein the bulking agent is selected from mannitol, trehalose, raffinose, and sucrose, and mixtures thereof.

15. (previously presented) The method of Claim 14 wherein the bulking agent is selected from trehalose, raffinose, and sucrose.

16. (cancelled)

17. (previously presented) The method of Claim 13 wherein the acute pre or postcapillary occlusions include transplantations or retina thrombosis.

18. (previously presented) The method of Claim 13, wherein the method further comprises administering to said patient by continuous infusion for about one to about forty-eight hours a dosage of about 0.01 mg/kg/hr to about 0.05 mg/kg/hr of activated protein C.

19. (previously presented) The method of Claim 18, wherein the activated protein C is administered in a bolus injection followed by said continuous infusion.

20. (previously presented) The method of Claim 13 wherein said disease state is thrombotic stroke.

21. (previously presented) The method of Claim 13 wherein said disease state is deep vein thrombosis.

22. (previously presented) The method of Claim 13 wherein said disease state is pulmonary embolism.

23. (previously presented) The method of Claim 13 wherein said disease state is peripheral arterial thrombosis.

24. (previously presented) The method of Claim 13 wherein said disease state is emboli originating from the heart or peripheral arteries.

25. (previously presented) The method of Claim 13 wherein said disease state is acute myocardial infarction.

26. (previously presented) The method of Claim 13 wherein said disease state is disseminated intravascular coagulation.

27. (previously presented) The method of Claim 13 wherein said disease state is acute pre or postcapillary occlusions.

28. (previously presented) The method of Claim 27 wherein the acute pre or postcapillary occlusions include transplantations or retina thrombosis.

29. (new) The method of claim 13, wherein said formulation further comprises a buffer selected from Tris-acetate, sodium citrate and sodium phosphate, or combinations thereof.

30. (new) The method of claim 29, wherein said formulation further comprises a buffer such that upon reconstitution said formulation has a pH of about 5.5 to 6.5.

31. (new) The method of claim 29, wherein said formulation contains less than 10% by weight of the autodegradation products des(1-9) and des(1-10).